Markets:

Overview

News

Currencies

International

Treasuries

First Trust Amex Biotech Index Fund (NY:FBT)

270.44 +1.19 (+0.44%)

Delayed Quote Updated: 9:30 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about First Trust Amex Biotech Index Fund

< Previous 1 2 Next >

Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT? ↗

Today 8:30 EDT

IXJ offers diversified global exposure at lower cost, while FBT concentrates on biotech with higher volatility and stronger recent returns.

Via The Motley Fool

Topics ETFs

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH ↗

October 10, 2026

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

Via The Motley Fool

Topics ETFs

Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? ↗

September 10, 2026

One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

Via The Motley Fool

Topics ETFs

Why Did SRPT Stock Rise 6% In Pre-Market Today? ↗

January 26, 2026

Via Stocktwits

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? ↗

January 12, 2026

Via Stocktwits

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets? ↗

August 19, 2026

XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.

Via The Motley Fool

Topics ETFs

IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? ↗

August 13, 2026

FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.

Via The Motley Fool

Topics ETFs

State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio? ↗

July 29, 2026

FBT delivered 48.5% returns over one year but carries a 0.55% expense ratio and experiences greater volatility. XLV offers lower costs, with an 0.08% expense ratio, as well as broader diversification...

Via The Motley Fool

Topics ETFs

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT? ↗

July 23, 2026

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? ↗

July 21, 2026

One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.

Via The Motley Fool

Topics ETFs

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? ↗

July 21, 2026

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

Via The Motley Fool

Topics ETFs

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance? ↗

July 12, 2026

First Trust's 30-stock strategy delivered 53.2% returns over one year, but comes with higher concentration risk and a steeper 11-basis-point fee.

Via The Motley Fool

Topics ETFs

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026? ↗

July 08, 2026

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.

Via The Motley Fool

Topics ETFs

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? ↗

June 04, 2026

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration—key factors shaping their long-term investor appeal.

Via The Motley Fool

Topics ETFs Stocks

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗

March 16, 2026

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy.

Via Stocktwits

Topics Death

SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗

February 18, 2026

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Via Stocktwits

POET Technologies Lands $5 Million Order As AI Demand Surges ↗

October 22, 2025

POET Tech received $5M order for POET Infinity engines. They cater to AI networks, data centers. CEO touts tech & customer trust.

Via Benzinga

Topics Artificial Intelligence

Bitcoin Drops Below $114K With XRP, Solana, Dogecoin Leading The Slide – ETF Outflows Hit $1.3B Over the Last 4 Days ↗

August 06, 2025

Via Stocktwits

Topics ETFs

Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish ↗

April 15, 2025

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize...

Via Stocktwits

Topics Stocks

Healthcare Sector Trying To Bounce Back ↗

March 09, 2025

I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.

Via Talk Markets

Topics ETFs Stocks / Equities

Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? ↗

March 04, 2025

Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as...

Via Talk Markets

Topics ETFs Stocks / Equities

NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst ↗

February 24, 2025

Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.

Via Benzinga

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗

April 13, 2023

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...

Via Benzinga

Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗

April 13, 2023

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.

Via Benzinga

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...

Via Benzinga

FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗

April 06, 2023

Via Benzinga

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...

Via Benzinga

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

Lots Of & Increasing Evidence That Stocks Are Bottoming For Now ↗

May 23, 2022

On Friday we saw one of the more violent trading days. Stocks jumped at the open, sold off sharply to new lows, and then rocketed back in the last hour to close basically unchanged.

Via Talk Markets

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.